What are the key elements to include in a biotech startup pitch deck?

A biotech startup pitch deck should include a carefully sequenced set of slides that address both the scientific credibility and the commercial viability of your venture, because investors in this space evaluate both dimensions simultaneously. Unlike a SaaS pitch, where a live demo can carry the room, biotech founders must build a narrative that translates complex biology into a compelling business opportunity. At minimum, your deck needs: a clear problem statement grounded in patient or market data, your proposed mechanism of action, clinical or preclinical evidence, regulatory pathway, competitive landscape, business model, team credentials, and a detailed use-of-funds slide tied to specific milestones.

The problem and market slides deserve more attention than most founders give them. Investors need to understand the disease burden in concrete terms — prevalence rates, current standard of care, unmet clinical need, and the economic cost of that unmet need. For example, if you are targeting a rare orphan disease with fewer than 200,000 U.S. patients, you must show that FDA orphan drug designation is achievable and that premium pricing supports a viable market despite small patient volume. Conversely, if you are in an indication like non-alcoholic steatohepatitis (NASH) where multiple Phase 3 trials have failed, you need to proactively address why your mechanism avoids those failure modes. Investors will ask, so answer before they do.

The science and clinical data slides are where biotech pitches are won or lost. Preclinical data should clearly indicate the model used — whether in vitro cell assay, mouse xenograft, or non-human primate study — and explain why that model is predictive. If you have Phase 1 safety data or biomarker readouts from a Phase 1b, present the dose-response curve and adverse event profile. Critically, include a development timeline that shows your next major value-creating milestone: for example, ‘IND filing in Q3 2025, Phase 1 cohort 1 data by Q2 2026.’ Investors fund milestones, not science in the abstract, so every data point should connect to a decision gate that de-risks the asset and increases valuation.

The regulatory and IP strategy slides are often underdeveloped but critically important. Specify your regulatory pathway — 505(b)(1), Breakthrough Therapy Designation eligibility, or Accelerated Approval — because this directly affects your development timeline and capital requirements. On intellectual property, note the composition-of-matter patent expiration date and any method-of-use claims that extend exclusivity, since a compound going off-patent in three years carries a very different risk profile than one with 15 years of runway. These details signal to investors that you understand the full commercial landscape, not just the biology.

• Lead with a one-slide executive summary that states the indication, mechanism, current stage, and funding ask so investors can orient themselves before absorbing detailed science slides.
• Include a competitive landscape matrix comparing your asset to at least four competitors on dimensions like efficacy endpoint, dosing frequency, safety profile, and stage of development.
• Show your regulatory milestone map as a Gantt-style timeline annotated with go/no-go decision points, capital requirements per phase, and expected data readout dates.
• Present your team slide with PI publication record, prior drug approval experience, and any key scientific advisory board members who have domain credibility in your specific indication.
• Use a clear mechanism-of-action diagram — even a simplified pathway schematic — that shows exactly where and how your molecule intervenes, making the biology accessible to non-specialist investors.
• Include a capitalization and financing history slide showing prior investors, amounts raised, and valuation at each round to demonstrate momentum and investor quality.
• Close with a specific use-of-funds breakdown: for instance, ‘60% toward Phase 1 trial costs, 25% toward CMC scale-up, 15% toward G&A over 24 months.’

A strong biotech pitch deck is ultimately a risk-mitigation story packaged as a compelling opportunity. Your next step should be building a 12-15 slide deck, then testing it with a scientific advisor who has no prior knowledge of your work — if they cannot explain your mechanism back to you after one viewing, simplify the science slides. Note that this framework applies primarily to therapeutics companies seeking venture or crossover financing; platform technology companies or diagnostics startups have distinct investor expectations and may need to restructure the deck around partnership revenue or payer reimbursement models rather than a single asset pipeline.